Vestibular Migraine

Migraine is a brain condition usually associated with severe headaches. But not every migraine attack involves a headache, and many people with migraine experience attacks of vertigo — sometimes only vertigo — that come and go in the same pattern as their headaches once did. This is vestibular migraine.

Vestibular migraine is the most common cause of recurrent vertigo that is not from the inner ear. It affects roughly 1% of the general population and up to 10% of patients with migraine. Attacks last anywhere from five minutes to three days; some patients have only a few attacks per year, others have several per month.

The diagnosis is made by recognising the pattern of attacks, not by any specific test. Examination between attacks is usually normal. The good news is that vestibular migraine responds to the same preventive medications used for headache migraine — beta-blockers like propranolol, topiramate, and others. Many patients also identify and avoid triggers (sleep deprivation, stress, certain foods, hormonal changes) and find this alone helps substantially.

Vestibular migraine is now recognised as one of the most common vestibular disorders. Population prevalence estimates range from 0.98% (the seminal Neuhauser 2006 study) to 2.7% in different methodologies.4 Approximately 10% of all patients with migraine experience migrainous vertigo at some point, and approximately 20% of patients presenting to vestibular clinics with recurrent vertigo have vestibular migraine as their final diagnosis.3,5

The diagnostic criteria, jointly developed by the Bárány Society and the International Headache Society in 2012 and updated in 2022, define two categories: definite vestibular migraine (all four criteria met) and probable vestibular migraine (a relaxation that allows diagnosis when either the migraine history or the migraine features during attacks are absent).1,2 Vestibular migraine appears in the appendix of ICHD-3 as a developing diagnosis — formal inclusion in the main body of ICHD requires further accumulated evidence, but the appendix entry is the authoritative classification for clinical use.6

Three features make vestibular migraine particularly important to recognise. First, it is common — far more common than Ménière's, far more common than vestibular schwannoma, far more common than most other episodic vestibular diagnoses combined. Second, it is treatable — well-evidenced prophylactic agents (propranolol, topiramate) substantially reduce attack frequency. Third, misdiagnosis matters: vestibular migraine patients inappropriately treated as Ménière's with intratympanic gentamicin lose vestibular function unnecessarily.8

The pathophysiology of vestibular migraine remains the subject of active research. Three converging hypotheses shape the current understanding. The cortical spreading depression mechanism — well-established for migraine aura — likely contributes to the perceptual disturbance during vestibular migraine attacks, with spreading depression affecting central vestibular processing areas (parietoinsular vestibular cortex, the vestibular nuclei). The trigeminovascular activation theory implicates the same neuropeptides (CGRP, substance P) that drive headache, with vestibular manifestations attributed to CGRP-mediated modulation of the vestibular nuclei and inner ear vasculature — the rationale for trialling anti-CGRP monoclonal antibodies in refractory vestibular migraine. The ion-channel dysfunction theory draws on the familial hemiplegic migraine genetics (CACNA1A, ATP1A2) and proposes that vestibular migraine shares aspects of episodic ataxia type 2, where calcium-channel mutations produce both migraine phenomena and vestibular episodes.

Clinically, the lifespan epidemiology is distinctive. Vestibular migraine has the broadest age distribution of any vestibular disorder — onset can occur in childhood (as benign paroxysmal vertigo of childhood, the migraine equivalent of recurrent vertigo with normal examination, often evolving into typical migraine in adolescence) or in later adulthood (after menopause, women whose typical migraines have remitted may develop vestibular migraine). The female-to-male ratio is approximately 3:1, mirroring migraine generally.7

The longitudinal pattern matters for diagnosis: many patients describe a personal history of childhood motion sickness, a peak of headache migraine in their 20s and 30s, and the emergence of vestibular attacks in their 40s and 50s — sometimes as headaches diminish. This temporal relationship — vertigo replacing headache rather than accompanying it — is the most common reason patients fail to recognise their own diagnosis. Many do not connect the two until specifically asked.

For a doctor to diagnose "definite" vestibular migraine, a patient needs to meet all of the following:

• At least five episodes of vertigo of moderate or severe intensity, each lasting 5 minutes to 72 hours;
• A history of migraine (the headache kind);
• Migraine features (headache, light/noise sensitivity, or visual aura) during at least half of the vertigo episodes;
• No better alternative explanation.

If the patient has the episodes but not the migraine history, or has the episodes and the history but the episodes don't have migraine features, the diagnosis is called "probable" instead of definite. Either way, the treatment is the same.

The full diagnostic criteria — the version applied by the criteria checker above — are:1,2

Vestibular migraine (definite):

1. At least 5 episodes of vestibular symptoms of moderate or severe intensity, lasting 5 minutes to 72 hours;
2. Current or past history of migraine with or without aura according to ICHD criteria;
3. One or more migraine features with at least 50% of the vestibular episodes:
   • Headache with at least 2 of: unilateral location, pulsating quality, moderate or severe pain intensity, aggravation by routine physical activity;
   • Photophobia and phonophobia;
   • Visual aura.
4. Not better accounted for by another vestibular or ICHD diagnosis.

Probable vestibular migraine requires criteria 1 and 4 above plus EITHER criterion 2 (migraine history) OR criterion 3 (migraine features during attacks) — but not necessarily both.

Three operational points. First, criterion 3's photophobia-and-phonophobia requirement is conjunctive, not disjunctive — both must be present in an attack to count it. Second, the duration window (5 min–72 h) does heavy diagnostic work: attacks < 5 min suggest BPPV or TIA; > 72 h suggest AUVP, stroke, or PPPD. Third, the exclusion criterion is the rate-limiting step in most clinic practice: many vestibular migraine diagnoses are made only after Ménière's has been excluded by audiometry showing no persistent low-frequency SNHL.

The criteria's strictness is deliberate — the Bárány/IHS framers chose specificity over sensitivity to preserve the diagnosis's research value and to discourage diagnostic creep. In clinical practice this produces a meaningful population of patients with "vestibular migraine — clinically diagnosed but criteria not met". These patients are typically managed identically to definite or probable patients; the criteria threshold matters more for research enrolment, clinical trials, and billing than for treatment decisions.

Three classification subtleties deserve mention. Patients with migraine and BPPV occurring together is common (migraineurs have a higher prevalence of BPPV than non-migraineurs), and should be diagnosed as both — the BPPV is positional and short-lived, the migrainous vertigo is spontaneous and longer. Patients with both vestibular migraine and Ménière's disease (criteria for each met independently) are increasingly recognised — overlap rates of 30–40% in series that apply both sets of criteria. And benign recurrent vertigo of adults (Slater 1979) — recurrent vertigo without migraine history or features — is a probable vestibular migraine presentation by current criteria, and responds to migraine prophylaxis in most cases.

Vestibular migraine looks similar to a few other vestibular conditions, and getting the diagnosis right matters because the treatments differ. The most important distinction is from Ménière's disease. Both cause episodes of vertigo lasting hours, but Ménière's also causes hearing loss that builds up over time on one side, with ringing and a feeling of pressure in the same ear. Vestibular migraine doesn't damage hearing.

The Ménière's vs vestibular migraine differential is the most clinically consequential decision in episodic vestibular medicine. Symptom overlap is substantial — both cause spontaneous episodic vertigo lasting hours, both can produce tinnitus and aural fullness, both can be accompanied by headache. The cleanest discriminators are:

• Audiometric evidence of progressive low-frequency SNHLin Ménière's — present in essentially every confirmed case, absent in vestibular migraine. A series of audiograms across attacks is more informative than any single one.9
• Attack duration distribution: Ménière's attacks are 20 minutes to 12 hours; vestibular migraine attacks span 5 minutes to 72 hours. Attacks > 12 h favour vestibular migraine; < 20 min favours vestibular migraine or BPPV.
• Migraine features (headache, photo/phonophobia, aura) during attacks favour vestibular migraine; their absence does not exclude it.
• Caloric paresis on testingfavours Ménière's; vestibular migraine patients have largely normal caloric responses interictally.
• Response to migraine prophylaxisis a diagnostic test in itself — patients diagnosed as Ménière's who respond to propranolol or topiramate often have vestibular migraine.8

Other differentials worth considering. BPPV is positional and short-lived (< 1 min). Posterior circulation TIA is brief, recurrent, and accompanied by other neurological symptoms (visual deficits, dysarthria, ataxia) — particularly important to exclude in patients over 50 with vascular risk factors. Vestibular paroxysmia produces very brief (seconds) attacks attributed to neurovascular cross-compression and responds dramatically to carbamazepine. PPPD produces persistent rather than episodic dizziness, although it can be triggered by an initial vestibular migraine episode.

The clinical reality is that vestibular migraine and Ménière's coexist more often than the textbooks suggest. The Radtke 2012 follow-up of patients diagnosed with vestibular migraine found that 13% had also developed Ménière's criteria by 9-year follow-up, often with progressive low-frequency SNHL accumulating across attacks.7Migraine is roughly twice as prevalent in patients with Ménière's as in the general population, suggesting genuine pathophysiological overlap rather than coincidence.8

Two clinical strategies emerge. First, serial audiometry in any patient with episodic vertigo whose attacks last hours — the cleanest objective separator. Second, in ambiguous patients, a 3-month trial of migraine prophylaxis (propranolol or topiramate) is both diagnostic and therapeutic — responders are very likely to have a migrainous component to their disease regardless of whether they also have Ménière's. Avoid intratympanic gentamicin in any patient where vestibular migraine remains in the differential — irreversible vestibular destruction in a migraine patient with preserved peripheral function is a permanent iatrogenic injury.

Treatment has two parts. First, identifying and avoiding personal triggers — common ones include not enough sleep, stress, certain foods (caffeine, alcohol, aged cheeses, processed meats with nitrates), skipping meals, and hormonal changes. Some patients find that managing these alone reduces attacks substantially.

Second, if attacks are still frequent or disabling, preventive medication. The most effective are propranolol (a blood pressure pill that also prevents migraine) and topiramate (an anti-seizure medicine, also used for migraine). Both are taken daily; effects build up over weeks. Acute attacks can be managed with anti-nausea medications and rest in a dark, quiet room — much like a regular migraine.

Vestibular migraine management follows the same broad structure as headache migraine: lifestyle modification, acute attack management, and prophylaxis for frequent or severe disease.

Lifestyle and trigger management is first-line and well-evidenced for migraine generally, though specific to-vestibular-migraine evidence is weaker. A migraine diary identifies patient-specific triggers across sleep, stress, dietary, hormonal, environmental (weather changes, barometric pressure), and sensory (bright lights, strong odours) domains. Regularising sleep timing and ensuring adequate hydration have the strongest informal evidence base.

Acute attack treatment mirrors typical migraine: an antiemetic (prochlorperazine, metoclopramide, ondansetron) and a triptan if headache is part of the attack. Triptans have been tested specifically in vestibular migraine with limited evidence of benefit but no contraindication. Benzodiazepines provide rapid symptomatic relief and are reasonable for severe attacks, although chronic use should be avoided.

Prophylaxis is indicated for attacks occurring more than 2–3 times per month, attacks of long duration, or attacks substantially affecting quality of life. The 2025 systematic review by Almohammed and colleagues identified propranolol and topiramate as first-line agents, with moderate-quality evidence supporting both.11 The Salviz 2016 RCT compared propranolol vs venlafaxine head-to-head and found equivalent vestibular outcomes, with venlafaxine showing additional benefit in the emotional/depressive dimension.10

Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) — transformative for headache migraine prophylaxis — show promising early evidence in vestibular migraine but the trial data is limited. Reasonable for refractory cases where two or three conventional agents have failed.11

Three practical points in selecting and titrating prophylactic therapy. First, choose by patient profile — propranolol for the hypertensive patient with anxiety; topiramate for the overweight patient (modest weight loss benefit) but avoid in patients with cognitive concerns or kidney stones; venlafaxine where depressive symptoms accompany the vestibular symptoms; flunarizine (where available — not in the US) for refractory cases or patients who tolerate the others poorly.

Second, set realistic expectations. Most patients on effective prophylaxis see a 50% reduction in attack frequency, not complete remission. A trial period of at least 8–12 weeks at therapeutic dose is required before judging response — premature discontinuation is one of the most common reasons for treatment failure. The Dizziness Handicap Inventory (DHI) is a validated quantitative outcome that's worth tracking.

Third, vestibular rehabilitation is an underused adjunct. Patients with persistent inter-ictal imbalance, motion sensitivity, or PPPD-like features benefit from a structured VRT programme tailored to migraine sensitivity (avoiding aggressive habituation that can trigger attacks). The combination of pharmacological prophylaxis and graded VRT outperforms either alone in observational series.

Refractory vestibular migraine — failing > 3 conventional agents at adequate dose and duration — warrants reconsideration of the diagnosis before escalating to CGRP monoclonal antibodies or onabotulinumtoxinA. The most common reason for apparent treatment refractoriness in our experience is an alternative or overlapping diagnosis (PPPD, comorbid Ménière's, or medication-overuse from frequent triptan use).